Pediatrix Medical Group, Inc. (MD) SEC Filings

Young Sylvia Jean reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group, Inc. reported that director Sylvia Jean Young received a grant of 472 restricted shares of common stock on August 12, 2026. The award was granted under the company’s Second Amended and Restated 2008 Incentive Compensation Plan and reflects an increase to her annual equity award. These restricted shares will vest on May 7, 2027, and her directly held common stock position after the grant is 48,286 shares.

SANSONE GUY P reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group, Inc. reported that director Guy P. Sansone received an equity award of 472 shares of Common Stock on August 12, 2026. The restricted shares were granted under the Second Amended and Restated 2008 Incentive Compensation Plan and will vest on May 7, 2027, bringing his post-grant direct holdings to 87,416 shares.

Pediatrix Medical Group delivered modest growth for the quarter and six months ended June 30, 2026. Net revenue reached $487.8 million in Q2 and $964.0 million year‑to‑date, both up 4.0% from 2025, driven by acquisitions and same‑unit reimbursement gains, partly offset by lower patient volumes, especially in neonatology.

Q2 income from operations slipped to $56.9 million with an 11.7% operating margin versus 12.8% a year earlier, as practice salaries and benefits and transformational and restructuring costs increased. However, six‑month net income improved to $69.4 million and diluted EPS to $0.85, with Adjusted EBITDA rising to $134.6 million and Adjusted EPS to $1.07.

Cash and cash equivalents fell to $288.9 million, and operating cash flow from continuing operations turned to a $3.2 million use of cash, mainly from incentive compensation and working capital. The company spent $61.7 million repurchasing 2.8 million shares, while maintaining leverage with a $184.4 million Term A Loan, $400.0 million of 2030 Notes and an undrawn $450.0 million revolver. Days sales outstanding improved to 42.5 days, and management expects existing cash, cash generation and credit capacity to cover needs for at least the next 12 months.

Pediatrix Medical Group reported second-quarter 2026 net revenue of $487.8 million, up 4.0% from $468.8 million a year earlier. Net income was approximately $40 million, or diluted EPS of $0.49, while Adjusted EPS was $0.63 and Adjusted EBITDA was about $76 million.

Management attributed growth to 2.1% non-same-unit revenue expansion from recent acquisitions and 1.9% same-unit revenue growth. Same-unit revenue from reimbursement-related factors rose 4.0%, driven by improved cash collections, a more favorable payor mix and higher patient acuity, while same-unit patient volume declined 2.1% and commercial and other non-government payors increased by 135 basis points.

As of June 30, 2026, cash and cash equivalents were $288.9 million, total debt was $584.2 million and shareholders’ equity was $881.0 million. The company also outlined a forward-looking 2026 Adjusted EBITDA range between $280 million and $300 million.

Pediatrix Medical Group, Inc. reports that Mary Ann E. Moore, previously Executive Vice President, General Counsel, Chief Administrative Officer and Secretary, has entered into a Separation Agreement with subsidiary PMG Services, Inc. Under this agreement, she will serve in an advisory role until October 31, 2026, when her employment with the company will end.

The company states that Ms. Moore’s transition is treated as a termination without cause under her Second Amended and Restated Employment Agreement, and she will receive the benefits specified in that agreement. Pediatrix also reports the appointment of David Haddock as Executive Vice President, General Counsel and Secretary.

Pediatrix Medical Group, Inc. provided an update on second quarter 2026 business trends, noting that its payor mix remained stable and unchanged relative to recent historical trends and internal expectations, despite reports of adverse utilization and reimbursement shifts elsewhere in the healthcare sector.

The company stated it has not experienced unfavorable payor mix shifts or material changes in other net revenue-related trends. Pediatrix reaffirmed its full year 2026 outlook for Adjusted EBITDA in a range of $280 million to $300 million, supported by a reconciliation from net income. Pediatrix plans to discuss results for the quarter ended June 30, 2026 on an investor conference call and webcast on August 4, 2026 at 9:00 a.m. ET.

Pediatrix Medical Group Inc is reported to have a significant institutional holder, as Dimensional Fund Advisors LP may be deemed the beneficial owner of 4,220,311 shares of its common stock, representing 5.1% of the outstanding class.

Dimensional reports sole voting power over 4,117,448 shares and sole dispositive power over 4,220,311 shares, with no shared voting or dispositive power. The shares are owned by investment funds that Dimensional advises, and Dimensional disclaims beneficial ownership of these securities other than for Section 13(d) reporting purposes.

Haddock David reported acquisition or exercise transactions in this Form 4 filing.

Pediatrix Medical Group EVP David Haddock received new equity awards. On 2026-06-22, he was granted 20,036 shares of common stock at no cost as restricted shares under the company’s incentive compensation plan.

He also received 51,000 Performance Share Units, each tied to one common share. These PSUs vest after three years only if both service and stock performance conditions are met. Shares are earned in one-third increments based on Pediatrix’s stock trading at 115%, 125% and 135% of $22.66 for at least 20 consecutive trading days before the third anniversary of the grant date.

Pediatrix Medical Group, Inc. executive David Haddock, who serves as EVP, General Counsel and Corporate Secretary, submitted an initial Form 3 insider ownership report. The filing lists no transactions or derivative positions, functioning as a baseline disclosure of his status as a reporting officer.